Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

计划入组 35 人 · 首次发布于 2022 年 8 月 23 日

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

计划入组 357 人 · 首次发布于 2025 年 3 月 6 日

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

计划入组 90 人 · 首次发布于 2022 年 12 月 1 日

Ribociclib(Kisqali 200 Mg Daily Dose Carton, Kisqali Femara Co-pack, Kisqali)

C₂₃H₃₀N₈O · Rx

Abemaciclib(Verzenio, Verzenios)

C₂₇H₃₂F₂N₈ · Rx

HER2+ Breast Cancer(Diakonos)

JAPAN BREAST CANCER RESEARCH GROUP

Japan

ANZ BREAST CANCER TRIALS GROUP LIMITED

Australia

International Breast Cancer Research Foundation

United States

Dalpiciclib Plus Letrozole Shows Promise in Phase II Trial for HR+/HER2- Breast Cancer

Genentech's Inavolisib Receives FDA Approval for Advanced HR+, HER2- Breast Cancer

Researchers Identify Key Resistance Mechanism to CDK4/6 Inhibitors in HR+/HER2- Breast Cancer